Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma

Leukemia

Volumn 28, Issue 5, 2014, Pages 993-1000

  Atanackovic, D ^a   Luetkens, T ^a   Kroger N ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

immunotherapy; multiple myeloma; programmed death 1; tumor immunology

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; LIGAND BINDING; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

ANIMALS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84899910420     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.310     Document Type: Review

References (134)

1. Blade J, Cibeira MT, Fernandez de Larrea C, Rosinol L. Multiple myeloma. Ann Oncol 2010; 21: Vii313-vii319.
2. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood 2011; 117: 5573-5581.
3. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A. et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-959.
4. Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: Current status and future potential. Am J Hematol 2012; 87: 1089-1095.
5. Trono D, Kapanci Y. [Causes of death in cases of lymphoma, myeloma and Hodgkin disease. Study of 218 cases]. Schweiz Med Wochenschr 1983; 113: 701-708.
6. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975; 50: 29-40.
7. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
8. Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012; 2012: 196063.
9. Paradisi F, Corti G, Cinelli R. Infections in multiple myeloma. Infect Dis Clin North Am 2001; 15: 373-384, vii-viii.
10. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
11. Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol (Paris) 1999; 47: 98-108.
12. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006; 34: 1289-1295.
13. Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N. et al. The cytokine/ chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010; 38: 860-867.
14. Munshi NC. Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 51-69.
15. Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C. et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med 1975; 293: 887-892.
16. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211-1225.
17. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981; 71: 935-940.
18. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S. et al. Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570-1582.
19. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K. et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82: 1261-1265.
20. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O. et al. Longitudinal analysis of tetanus-And influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol 2012; 2012: 134081.
21. Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol 1994; 97: 21-24.
22. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008; (4): CD006501.
23. Murakami H, Ogawara H, Hiroshi H. Th1/Th2 cells in patients with multiple myeloma. Hematology 2004; 9: 41-45.
24. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H. et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12-20.
25. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: Inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107: 2432-2439.
26. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B. et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002; 100: 230-237.
27. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J. et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-2998.
28. O?Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-805.
29. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
30. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK. et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2005; 107: 301-304.
31. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA. et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949.
32. Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, De Rosa L. et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med 2012; 10: 247.
33. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM. HIV-Associated monoclonal gammopathy: A retrospective analysis of 25 patients. Clin Infect Dis 2006; 43: 1198-1205.
34. Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: From benign gammopathy to multiple myeloma. AIDS Read 2004; 14: 372-374, 377-379.
35. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B. et al. Blood levels of immune cells predict survival in myeloma patients: Results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23-28.
36. Kay NE, Leong T, Bone N, Kyle RA, Greipp PR, Van Ness B. et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 1998; 100: 459-463.
37. Corso A, Castelli G, Pagnucco G, Lazzarino M, Bellio L, Klersy C. et al. Bone marrow T-cell subsets in patients with monoclonal gammopathies: Correlation with clinical stage and disease status. Haematologica 1997; 82: 43-46.
38. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G. et al. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res 2007; 13: 5348-5354.
39. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E. et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194-4197.
40. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: Implications for anti-CD200 therapy. J Immunol 2008; 180: 699-705.
41. Muller M, Gounari F, Prifti S, Hacker HJ, Schirrmacher V, Khazaie K. EblacZ tumor dormancy in bone marrow and lymph nodes: Active control of proliferating tumor cells by CD8+ immune T cells. Cancer Res 1998; 58: 5439-5446.
42. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J. et al. Activated marrowinfiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005; 65: 2026-2034.
43. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002; 99: 13009-13013.
44. Pellat-Deceunynck C, Jego G, Harousseau JL, Vie H, Bataille R. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells. Clin Cancer Res 1999; 5: 705-709.
45. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D. et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435-1442.
46. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Perez-Simon JA. et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521-4530.
47. Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-Analysis of trials with biological assignment. Bone Marrow Transplant 2012; 48: 562-567.
48. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L. et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-Term follow-up. J Clin Oncol 2011; 29: 3016-3022.
49. Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH. et al. Partially T-cell-depleted allogeneic stem-cell transplantation for firstline treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728-1733.
50. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versusmyeloma effect: Proof of principle. Blood 1996; 87: 1196-1198.
51. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I. et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stemcell transplantation: Predictive factors for response and long-Term outcome. J Clin Oncol 2000; 18: 3031-3037.
52. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A. et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184.
53. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH. et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364.
54. Biernacki MA, Tai YT, Zhang GL, Alonso A, Zhang W, Prabhala R. et al. Novel myeloma-Associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3142-3150.
55. Broen K, Greupink-Draaisma A, Fredrix H, Schaap N, Dolstra H. Induction of multiple myeloma-reactive T cells during post-Transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplant 2012; 47: 1229-1234.
56. Tyler EM, Jungbluth AA, O?Reilly RJ, Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013; 121: 308-317.
57. Orsini E, Bellucci R, Alyea EP, Schlossman R, Canning C, McLaughlin S. et al. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res 2003; 63: 2561-2568.
58. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
59. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
60. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007; 179: 5064-5070.
61. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N. et al. Developmentally regulated expression of the PD-1 protein on the surface of doublenegative (CD4-CD8-) thymocytes. Int Immunol 1996; 8: 773-780.
62. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y. et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538-5545.
63. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J. et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9: 133-145.
64. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M. et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: Relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155: 172-182.
65. Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol 2007; 37: 2405-2410.
66. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR. et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643.
67. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
68. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
69. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
70. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
71. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB. et al. Tumorassociated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
72. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G. et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia 2006; 8: 190-198.
73. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947-2953.
74. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108: 19-24.
75. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094-5100.
76. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
77. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157.
78. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-Term follow-up. Cancer Res 2006; 66: 3381-3385.
79. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X. et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242.
80. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010; 7: 389-395.
81. Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquere K. et al. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One 2011; 6: E17621.
82. Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, Wang SF. et al. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 2011; 131: 1300-1307.
83. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 1757-1761.
84. Kang MJ, Kim KM, Bae JS, Park HS, Lee H, Chung MJ. et al. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl Oncol 2013; 6: 282-289.
85. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139: 667-676.
86. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
87. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505.
88. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T. et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64: 1140-1145.
89. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
90. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M. et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220-3224.
91. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
92. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C. et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 39: 1050-1058.
93. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-Associated T cells. Clin Cancer Res 2011; 17: 4232-4244.
94. Bentz M, Barth TF, Bruderlein S, Bock D, Schwerer MJ, Baudis M. et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30: 393-401.
95. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O?Donnell E. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-3277.
96. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE. et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013; 121: 1367-1376.
97. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G. et al. High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957-2964.
98. Takahashi H, Tomita N, Sakata S, Tsuyama N, Hashimoto C, Ohshima R. et al. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol 2013; 90: 286-290.
99. Alvaro T, Lejeune M, Salvado MT, Lopez C, Jaen J, Bosch R. et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350-5357.
100. Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012; 18: 678-687.
101. Han Y, Wu J, Bi L, Xiong S, Gao S, Yin L. et al. Malignant B cells induce the conversion of CD4+CD25-T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One 2011; 6: E28649.
102. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D. et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
103. Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011; 17: 1133-1145.
104. Benson Jr. DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B. et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294.
105. Kuranda K, Berthon C, Dupont C, Wolowiec D, Leleu X, Polakowska R. et al. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. Exp Hematol 2010; 38: 124-131.
106. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD. et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34: 409-418.
107. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A. et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27: 464-472.
108. Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M. et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contactdependent and antigen-presenting cell-independent. PLoS One 2012; 7: E35981.
109. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
110. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M. et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227-3237.
111. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N. et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103: 1787-1790.
112. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP. et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222-1232.
113. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T. et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62: 39-49.
114. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J. et al. The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
115. Idler I, Giannopoulos K, Zenz T, Bhattacharya N, Nothing M, Dohner H. et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010; 148: 948-950.
116. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
117. Patnaik A, Kang AP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M. et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012; 30(Suppl): Abstract 2515.
118. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH. et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
119. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
120. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
121. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
122. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG. et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 2011; 71: 5111-5122.
123. Hobo W, Norde WJ, Schaap N, Fredrix H, Maas F, Schellens K. et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J Immunol 2012; 189: 39-49.
124. Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH. et al. Polyfunctional CD4(+) T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012; 120: 2229-2239.
125. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/ programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620-5628.
126. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997-1008.
127. Robert C, Thomas L, Bondarenko I, O?Day S, M DJ, Garbe C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
128. Hodi FS, O?Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
129. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE. et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012; 30: 322-328.
130. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73: 3591-3603.
131. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
132. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A. et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190: 4899-4909.
133. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y. et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72: 5209-5218.
134. John LB, Devaud C, Duong CM, Yong C, Beavis PA, Haynes NM. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19: 5636-5646.